Project description
Novel biopsy procedure for targeted medicine diagnostics
Traditional biopsy for cancer and other diagnosis includes tissue fixation in formalin and embedding in paraffin for subsequent microscopy analysis of the morphology. Advancements in biomedicine make possible the broad analysis of biomolecules (biomarkers) for evaluation of disease progression but require tissue samples to be fresh or frozen immediately after biopsy. Current biopsy devices do not provide this option. Sorek Medical Systems Ltd. has developed biopsy devices capable of automatically splitting tissue sample in two for simultaneous chemical fixation and freezing preservation. The current EU-funded phase of the project will test and validate devices in clinical applications. These devices could have broad application for not only cancer diagnosis but also pharmaceutical development of biomarker-targeting drugs for targeted and personalised medicine.
Objective
Biopsy is a commonly used medical procedure for the diagnosis and characterization of cancer and other diseases. Traditionally, the tissue obtained is preserved by formalin fixation, embedded in paraffin, sectioned to thin tissue layers, and then analysed histologically under the microscope to evaluat overall tissue morphology. Current advancement in biomedicine makes it possible for greater use of molecular technologies. These technologies, allow for analysis of change in biomolecules (biomarkers) during cancer progression rather than tissue morphology alone. Laboratory analysis of biomarkers require tissue to be fresh (or fresh frozen) and rather not be preserved by formalin. In order to yield viable biomarker analysis tissue must be frozen as soon as possible because biomarkers are extremely sensitive to degradation. Current biopsy devices are not designed to meet these challenges of rapid freezing as a replacement to formalin fixation.
We, at Sorek Medical Systems Ltd., a 16-year-old R&D company based in Israel, developed two biopsy devices that automatically split the tissue sample in two during biopsy acquisition. Our technology allows chemical standard formalin fixation for histology. Sorek’s devices will be used by radiologists and surgeons, and by pharmaceutical companies seeking the development of biomarker-targeting drugs with the goal of improving personalized medicine and improving early diagnosis for breast, lung, chest, prostate, and other organs’ cancer disease. Our CryoBiopsy Phase 2 project will allow us to test and validate our devices which will require € 2.8 million investment. Our financial forecast show that after five-year commercialization we will generate a cumulative revenues of €57 million and will create 20 positions which will include engineers, technicians and our own sales personnel
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules
- natural sciences physical sciences optics microscopy
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences personalized medicine
- natural sciences biological sciences histology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20692 YOKNEAM ILLIT
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.